Title

Comparison Between Budesonide and Dexamethasone Treatments for Respiratory Discomfort After Extubation on Children
Comparison Between Inhaled Budesonide and Intravenous Dexamethasone Treatments for Postextubation Stridor in Children
  • Phase

    N/A
  • Study Type

    Interventional
  • Status

    Unknown status
  • Study Participants

    70
The study aims to analyze and compare the clinical effects of using inhaled budesonide or intravenous dexamethasone in the treatment of postextubation stridor on children admitted to the pediatric intensive care units at Hospital Municipal do M´Boi Mirim and Hospital Albert Einstein.
The investigators propose to perform a prospective, randomized, controlled and double-blind non inferiority study enrolling 70 children with postextubation stridor. The population will be divided in two groups: group 1 will receive inhaled budesonide and IV NS (intravenous normal saline) and group 2 will receive IV (intravenous) dexamethasone and inhaled normal saline. The study aims to analyze and compare (I would just say compare) the clinical effects of using inhaled budesonide or IV dexamethasone in the treatment of postextubation stridor on children admitted to the pediatric intensive care units at Hospital Municipal do M´Boi Mirim and Hospital Albert Einstein.
Study Started
Mar 31
2014
Primary Completion
Mar 31
2015
Anticipated
Study Completion
Mar 31
2016
Anticipated
Last Update
Feb 06
2014
Estimate

Drug Budesonide

The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.

  • Other names: Pulmicort

Drug Dexamethasone

The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.

  • Other names: Decadron, Hexadrol, Maxidex

Budesonide Active Comparator

2 mg of nebulized budesonide at 12/12 hours and 8 cc of intravenous normal saline.

Dexamethasone Active Comparator

This group will receive 0,15 mg/kg/dose of intravenous dexamethasone at 6/6 hours and 8 cc of nebulized normal saline at 12/12 hours.

Criteria

Inclusion Criteria:

patients intubated for periods longer than 24hs
age between 28 days and than 15 years
post extubation stridor must be clinically diagnosticated by a MD
informed consent must be obtained

Exclusion Criteria:

patients under palliative care
presence of neuromuscular disease
previous airway pathologies
epiglottitis, aspiration of foreign bodies
viral laryngitis
former airway surgery
patients previously included in the study within the same hospital admission
corticosteroid use in the 48hs preceding extubation
No Results Posted